4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile
C46H25N5O2 — CID 155159419
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile
4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile (PubChem CID 155159419) has the molecular formula C46H25N5O2 and a molecular weight of 679.74 g/mol. Its IUPAC name is 4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile.
Molecular Properties
| Compound Name | 4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile |
|---|---|
| PubChem CID | 155159419 |
| Molecular Formula | C46H25N5O2 |
| Molecular Weight | 679.74 g/mol |
| Exact Mass | 679.20 |
| IUPAC Name | 4-([1]benzofuro[2,3-a]carbazol-12-yl)-1-(4,6-diphenyl-1,3,5-triazin-2-yl)dibenzofuran-3-carbonitrile |
| SMILES | N#Cc1cc(-c2nc(-c3ccccc3)nc(-c3ccccc3)n2)c2c(oc3ccccc32)c1-n1c2ccccc2c2ccc3c4ccccc4oc3c21 |
| InChI | InChI=1S/C46H25N5O2/c47-26-29-25-35(46-49-44(27-13-3-1-4-14-27)48-45(50-46)28-15-5-2-6-16-28)39-34-19-9-12-22-38(34)53-43(39)40(29)51-36-20-10-7-17-30(36)32-23-24-33-31-18-8-11-21-37(31)52-42(33)41(32)51/h1-25H |
| InChIKey | UTGORUHXBRXTLC-UHFFFAOYSA-N |
| XLogP | 11.64 |
| TPSA | 93.67 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 53 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 679.74 |
| LogP ≤ 5 | 11.64 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155159419 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.